News
ARUXF
0.0093
NaN%
--
Acrux Lifts Cash and Revenue as It Refocuses Portfolio on Higher-Value Therapies
TipRanks · 01/28 23:38
Acrux Divests US Rights for Prilocaine and Lidocaine Cream
TipRanks · 12/11/2025 23:28
Acrux Director Acquires Significant Unlisted Options
TipRanks · 12/03/2025 02:07
Acrux Director’s Interest Update: Significant Rights Acquisition
TipRanks · 12/03/2025 00:58
Acrux Director Acquires Unlisted Rights, Aligning Interests with Company Goals
TipRanks · 12/03/2025 00:58
Acrux Ltd Announces Director’s Interest Change
TipRanks · 12/03/2025 00:57
Acrux Director Acquires Additional Unlisted Rights
TipRanks · 12/03/2025 00:47
Acrux Ltd Navigates Market Challenges with Strategic Focus
TipRanks · 11/24/2025 22:52
Acrux Ltd Director Increases Shareholding
TipRanks · 11/23/2025 22:48
Acrux Secures $0.4 Million Advance for R&D Initiatives
TipRanks · 11/12/2025 22:14
Acrux Reports Strong Profit Share Growth and Revenue Acceleration
TipRanks · 11/03/2025 23:07
Acrux Limited Reports Robust Quarterly Growth and Strategic Expansion Plans
TipRanks · 10/31/2025 05:17
Acrux Announces AGM Date and Director Nominations Deadline
TipRanks · 09/30/2025 08:44
Weekly Report: what happened at ARUXF last week (0908-0912)?
Weekly Report · 09/15/2025 10:37
Weekly Report: what happened at ARUXF last week (0901-0905)?
Weekly Report · 09/08/2025 10:39
Acrux Secures $3.04 Million R&D Tax Rebate for FY25
TipRanks · 09/03/2025 23:17
Weekly Report: what happened at ARUXF last week (0825-0829)?
Weekly Report · 09/01/2025 10:35
Acrux Ltd Releases Corporate Governance Statement for FY 2025
TipRanks · 08/29/2025 01:27
Weekly Report: what happened at ARUXF last week (0818-0822)?
Weekly Report · 08/25/2025 10:43
Weekly Report: what happened at ARUXF last week (0811-0815)?
Weekly Report · 08/18/2025 10:37
More
Webull provides a variety of real-time ARUXF stock news. You can receive the latest news about Acrux Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ARUXF
Acrux Limited is an Australia-based specialty pharmaceutical company. The Company is engaged in developing and commercializing a pipeline of topically applied pharmaceutical products. Its products include Lidocaine and Prilocaine Cream, USP 2.5%/2.5%, Lenzetto, Evamist, Dapsone Gel, 5% and Testosterone Topical Solution, 30 mg / 1.5 ml. Lidocaine and Prilocaine Cream USP (a eutectic mixture of lidocaine 2.5% and prilocaine 2.5%) is indicated as a topical anesthetic for use on normal intact skin for local analgesia and genital mucous membranes for superficial minor surgery and as pretreatment for infiltration anesthesia. Lenzetto (estradiol 1.53 mg/spray, transdermal spray, solution) is an estradiol spray for women which is used to treat moderate to severe hot flushes commonly associated with menopause. Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone.